Braveheart Bio (BRVE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$2.51
- Estimate
- $2.69
- Surprise
- -193.4%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Braveheart Bio (BRVE) reported a wider loss than forecast — diluted EPS of -$2.51 against the $2.69 estimate (a 193.4% shortfall).
Coverage in the report window
- Braveheart Bio Q2 EPS $(2.51) — benzinga, 2026-09-08
Where TrendMatrix's rating stands now
TrendMatrix currently rates BRVE Sell at 5.6/10; no pre/post engine snapshot brackets this report.
0 of the last 1 quarters beat the estimate; this quarter's -193.4% surprise compares with a -193.4% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Quality below floor (2.5 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -397.9%), Negative free cash flow
- Momentum score 3.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.02
- Price target
- $38.46
- Stop
- $25.13
- Upside to target
- +42.3%
- Reward-to-risk
- 2.8:1
Model outputs from TrendMatrix’s engine as of 2026-09-15 — shown for context, not personalized investment advice.
BRVE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.40B
- P/E (fwd)
- -13.4
- 52-week range
- $24.31–$32.00
- Off 52-week high
- 15.6%
- RSI (14)
- 48
- Volume vs avg
- 0.72×
- Score today
- 5.6/10